President Trump Orders Marijuana Rescheduling, Opens Research Path

President Donald Trump has issued an executive order for the “expeditious” reclassification of marijuana, moving it from Schedule I to Schedule III of the Controlled Substances Act. This significant decision ends nearly five decades of marijuana being categorized alongside dangerous drugs like heroin and MDMA. The change is expected to facilitate medical research and acknowledges the potential therapeutic benefits of cannabis.

Nearly four decades ago, Francis Young, then chief administrative law judge at the Drug Enforcement Administration (DEA), argued that marijuana should not be classified as a Schedule I substance. Young concluded that marijuana has accepted medical uses, particularly for treating nausea associated with cancer chemotherapy and spasticity from multiple sclerosis. Despite his findings, the DEA upheld marijuana’s Schedule I status until recent developments prompted a reevaluation.

In a review completed by the Department of Health and Human Services (HHS) in 2023, ordered by President Joe Biden, officials found “credible scientific support” for marijuana’s use in treating various medical conditions, including pain and nausea. HHS’s assessment highlighted that the vast majority of marijuana users do not experience dangerous outcomes. Consequently, the review recommended that marijuana be classified in Schedule III, which includes certain prescription drugs like ketamine and anabolic steroids.

Accepting this recommendation, Attorney General Merrick Garland proposed the reclassification in May 2024. Trump’s order effectively acknowledges that the federal government has overstated the hazards of marijuana while neglecting its potential benefits.

While this reclassification does not legalize marijuana for medical use outright, it will ease the burden on researchers by removing the stringent regulatory requirements associated with Schedule I substances. Nevertheless, the Food and Drug Administration (FDA) must approve specific cannabis-based products as prescription medicines for them to be legally authorized for medical use. Furthermore, state-licensed marijuana businesses will still operate in a legal gray area, remaining criminal enterprises under federal law, though they may benefit from reduced penalties.

Despite these limitations, the reclassification presents advantages for state-legal marijuana businesses, particularly regarding tax liabilities. Currently, these businesses face significantly high effective tax rates due to the inability to claim standard deductions. The new status may allow them to navigate these financial burdens more effectively.

In the wake of Young’s initial ruling, 40 states have legalized marijuana for medical use, and 24 states, representing a majority of the U.S. population, have also permitted recreational use. This growing acceptance contrasts sharply with the federal prohibition that many Americans now oppose.

Trump emphasized that his order “doesn’t legalize marijuana in any way, shape or form,” a statement that some may find disappointing given the evolving landscape around cannabis legislation. The reclassification marks a pivotal moment in the ongoing debate over marijuana and its place in American society, as advocates continue to push for broader legalization and acceptance of its medical uses.

As the situation develops, the implications of this change will likely resonate throughout the medical research community and the cannabis industry.